Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Micah A. Jacobs; Chad Wotkowicz; Egbert D. Baumgart; Brasil Silva Neto; Kimberly M. Rieger-Christ; Trisha Bernier; Michael S. Cohen; John A. Libertino; Ian C. Summerhayes(Profiled Author: Micah A Jacobs)
Journal of Urology. 2007;178(4):1510-1514.Abstract
Purpose: We established the frequency of mutation of the epidermal growth factor receptor in bladder cancer and determined whether the activation status of epidermal growth factor receptor confers sensitivity to erlotinib. Materials and Methods: The identification of mutations in the kinase domain (exons 18-21) of epidermal growth factor receptor was performed using single strand conformation polymorphism. The action of erlotinib was established within a bladder carcinoma cell panel using clonogenic assays and Western blot analysis. Results: In 112 invasive bladder tumors a total of 6 mutations in 4 patients (3.6%) were identified in exon 21. Erlotinib demonstrated concentration dependent inhibition of growth where three cell lines showed high and 2 showed low sensitivity to the drug. Erlotinib inhibited activation of epidermal growth factor receptor, mitogen activated protein kinase, Akt and STAT3. However, the activation status of Akt was maintained in cell lines that were insensitive to the inhibitory action of erlotinib and were characterized as having undergone epithelial-to-mesenchymal transition. Conclusions: Although mutations in the coding region of epidermal growth factor receptor are rare in invasive bladder tumors, differential sensitivity to erlotinib was recorded within a panel of cell lines. Maintenance of the phosphorylation status of Akt in the presence of erlotinib along with epithelial-to-mesenchymal transition correlates with insensitivity to growth inhibition in bladder carcinoma cell lines. Even in the absence of epidermal growth factor receptor mutations erlotinib shows potential as a therapeutic agent for the treatment of bladder cancer. © 2007 American Urological Association.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Pasi A. Jänne; Ana M. Borras; Yanan Kuang; Andrew M. Rogers; Victoria A. Joshi; Hema Liyanage; Neal Lindeman; Jeffrey C. Lee; Balazs Halmos; Elizabeth A. Maher; et al.Clinical Cancer Research. 2006;12(3 I):751-758.
Jacqueline C. Shultz; Rachel W. Goehe; D. Shanaka Wijesinghe; Charuta Murudkar; Amy J. Hawkins; Jerry W. Shay; John D. Minna; Charles E. ChalfantCancer Research. 2010;70(22):9185-9196.
Yunfei Zhou; Song Li; Yi P. Hu; Jing Wang; Jennie Hauser; Alexis N. Conway; Michelle A. Vinci; Lisa Humphrey; Elizabeth Zborowska; James K. V. Willson; et al.Cancer Research. 2006;66(1):404-411.
Appears in this Document